Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.

•Ankylosing spondylitis is one of the most frequent immune-mediated diseases associated to MS.•The use of TNF antagonists in patients with demyelinating diseases should be avoided.•Secukinumab might be effective in treating relapsing-remitting multiple sclerosis.•Secukinumab might be considered in case of concurrence of relapsing-remitting MS and ankylosing spondylitis.